Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
111,111,111
-
Number of holders
-
284
-
Total 13F shares, excl. options
-
80,007,908
-
Shares change
-
-504,088
-
Total reported value, excl. options
-
$5,562,070,253
-
Value change
-
-$38,817,221
-
Put/Call ratio
-
1.14%
-
Number of buys
-
126
-
Number of sells
-
-134
-
Price
-
$69.5
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q2 2022
353 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q2 2022.
NovoCure Ltd - Common Stock (NVCR) has 284 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 80,007,908 shares
of 111,111,111 outstanding shares and own 72.01% of the company stock.
Largest 10 shareholders include FMR LLC (12,542,005 shares), Capital World Investors (11,722,484 shares), BAILLIE GIFFORD & CO (9,116,230 shares), VANGUARD GROUP INC (8,109,739 shares), Capital International Investors (7,915,165 shares), BlackRock Inc. (7,333,151 shares), PRICE T ROWE ASSOCIATES INC /MD/ (2,331,367 shares), STATE STREET CORP (2,288,595 shares), Deep Track Capital, LP (1,341,300 shares), and GEODE CAPITAL MANAGEMENT, LLC (1,258,527 shares).
This table shows the top 284 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.